Ehsan Shabani

Dr. Ehsan Shabani


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2026 in Chemosensors
Verified
Journal Article
Open access
PDF file
Sayeh DowlatshahiSayeh Dowlatshahi
Sayeh Dowlatshahi
ESEhsan Shabani
Ehsan Shabani
MAMohammad Jafar Abdekhodaie
Mohammad Jafar Abdekhodaie
MSMohammad Ali Shafiee
Mohammad Ali Shafiee
Prostate cancer is a neoplastic disease that generally remains asymptomatic until its late-stage emergence. Among the techniques approved to date for prostate cancer diagnosis, prostate-specific antigen (PSA) screening is the most established method for its early detection. Currently, centralized clinical laboratories measure serum PSA using costly, time-consuming, multi-step immunoassays that rely heavily on lab technicians and highly sophisticated equipment. To address this issue, we developed a proof-of-concept, disposable, label-free electrochemical biosensor for rapid detection of PSA-α1-antichymotrypsin complex (PSA-ACT) and free PSA (fPSA) using a single antigen incubation step. The immunosensors were based on HNO3-pretreated pencil graphite electrodes (PGEs) modified with graphene oxide (GO). Antigen concentrations were determined by measuring signals from the [Fe(CN)6]3−/4− redox probe using cyclic voltammetry (CV); the presence of antigen molecules decreased anodic current response at the PGE surface. A log-linear calibration response over 1–1000 ng/mL and an estimated limit of detection (LOD) of 2.48 ng/mL were observed for PSA-ACT, indicating a detection range of 2.48–1000 ng/mL for the tPSA biosensor. The fPSA immunosensor showed a log-linear calibration response over 0.1–1000 ng/mL; however, an analytical LOD below the lowest experimentally evaluated calibrator (0.1 ng/mL) was not determined. Analyses of the biosensors’ performance, selectivity, repeatability, and short-term storage stability, along with a preliminary comparison with commercial enzyme-linked immunosorbent assay (ELISA) kits using real human samples, provided early evidence supporting further development and optimization of these platforms for point-of-care (POC) PSA testing.